Traitement de l’aphtose par la thalidomide et la colchicine

Genvo, M.F.; Faure, Michel; Thivolet, J

doi:10.1159/000249696

Cited by 27 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thalidomide (α [N-phthalimido]-glutaramide) was synthesized in 1956 and sold as a sedative until 1961, when it was withdrawn from the market due to high teratogenicity and after having caused more than 10,000 cases of malformed babies 1 . After withdrawal, thalidomide was used in many countries for the treatment of several inflammatory dermatoses such as lepra reaction 2,3 , actinic prurigo 4 , aphtae and aphtosis 5,6 , pyoderma gangrenosum 7 , Weber-Christian disease 8 prurigo nodularis 9 Langerhans cell histiocytosis 10 and discoid lupus erythematosus 11 . More recently, due to the immunomodulatory effect, thalidomide has been used to treat graft-versushost disease 12 and patients with human immunodefficience virus 13 .…”

Section: And and M M M M Methods Ethods Ethods Ethods Ethodsmentioning

confidence: 99%

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

Sato¹,

Assis²,

Lourenzi³

et al. 1998

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

SUMMARY -Were selected 18 SLE patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photoprotectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who protectors and low doses prednisone and who presented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but represented good response to thalidomide but relapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female lapsed after withdrawal of the drug. All female patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide patients had no risk of pregnancy. Thalidomide was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose was reintroduced and maintained at low dose (25-100mg/day) for a minimum of 6 months.

show abstract

Section: And and M M M M Methods Ethods Ethods Ethods Ethodsmentioning

confidence: 99%

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

Sato¹,

Assis²,

Lourenzi³

et al. 1998

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…Unfortunately, not all patients benefit from colchicine, and at least 20% can have painful gastrointestinal symptoms or diarrhoea (Katz et al, 1994) and long-term use can induce infertility in young males. Combined colchicine and thalidomide therapy has been suggested to be of occasional benefit in the treatment of recalcitrant RAS (Genvo et al, 1984), although long-term therapy might be expected to give rise to clinically significant adverse side-effects.…”

Section: Colchicinementioning

confidence: 99%

Number VI Recurrent aphthous stomatitis

et al. 2005

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS; aphthae; canker sores) is a common condition which is characterized by multiple recurrent small, round or ovoid ulcers with circumscribed margins, erythematous haloes, and yellow or grey floors typically presenting first in childhood or adolescence. RAS occurs worldwide although it appears most common in the developed world. The aetiology of RAS is not entirely clear. Despite many studies trying to identify a causal microorganism, RAS does not appear to be infectious. A genetic predisposition is present, as shown by strong associations with genotypes of IL-1beta; IL-6 in RAS patients, and a positive family history in about one-third of patients with RAS. Haematinic deficiency is found in up to 20% of patients. Cessation of smoking may precipitate or exacerbate RAS in some cases. Ulcers similar to RAS may be seen in human immunodeficiency virus disease and some other immune defects, and drugs, especially non-steroidal anti-inflammatory drugs and nicorandil may produce lesions clinically similar to RAS. Topical corticosteroids can often control RAS. However, the treatment of RAS remains unsatisfactory, as most therapies only reduce the severity of the ulceration and do not stop recurrence.

show abstract

“…A very swift response of ulcerations to thalidomide is consistently reported, and thalidomide-induced suppression of the recurrence of ulcerations has been demonstrated in a placebo-controlled trial [6]. In other studies, patients received thalidomide and colchine concomitantly, with good results [7]. Reasoning that the activity controlling aphthae might be related to interference with leukocyte extravasation, we investigated the effect of thalidomide on focal leukocyte migration elicited by the local application of LPS to buccal mucosa of hamster cheek.…”

Section: Introductionmentioning

confidence: 99%